MedPath

BREYANZI

BREYANZI

Approved
DIN Number

02527138

Drug Class

Human

Market Date

Nov 19, 2024

Company
HC

bristol-myers squibb canada

Product Information

Detailed information about this Health Canada approved drug product, including dosage form, route of administration, and regulatory classification.

Product Details

Health Canada regulatory and product classification information

Regulatory Identifiers
DIN Number02527138
AIG Number0163641001
Classification & Schedule
C
Drug Class
Human
S
Schedule
Prescription ,  Schedule D
A
ATC Code
L01XL08 LISOCABTAGENE MARALEUCEL
Product Specifications
Dosage FormSuspension
Route of AdministrationIntravenous
AHFS Classification26:12.00
Health Canada Classification

ACTIVE INGREDIENTS (1)

LISOCABTAGENE MARALEUCELActive
Strength: 120000000 CELLS
Monograph: LISOCABTAGENE MARALEUCEL

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.